🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million infections annually. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the highly restricted treatment choices at this time.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on results released by a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The study involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to license and sell the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for public health efforts. This is considered crucial to lessen the impact of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea globally.